Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FXX489
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Administration
- Intravenous
01
Overview
FXX489 (also known as NNS309) is a radiopharmaceutical peptide-drug conjugate (RI-PDC) developed by PeptiDream in collaboration with Modulus Discovery. It is designed as a theranostic agent targeting Fibroblast Activation Protein (FAP), which is highly expressed on cancer-associated fibroblasts (CAFs) within the stroma of various solid tumors. The platform utilizes a peptide backbone conjugated to a chelator, allowing for labeling with different radioisotopes: Gallium-68 (68Ga) for PET imaging and diagnostic purposes, and Lutetium-177 (177Lu) for targeted radionuclide therapy. By targeting the tumor microenvironment rather than the cancer cells directly, FXX489 aims to overcome the delivery barriers posed by the dense stroma in tumors such as pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer.
- Other names
- 177Lu-FAP68Ga-FAPFAP-targeted RI-PDC177Lu-FXX48968Ga-FXX489
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on FXX489.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FXX489.